SIBU-MED (SIBUTRAMINE) (20 MG/TAB. – 60 TABS)

£44.99

+ Free Shipping
Category:

Sibu-Med (Sibutramine) 20 mg/Tablets – 60 Tablets: UK Product Information

Overview

Sibutramine is a centrally acting compound that was previously developed and marketed as a prescription weight-management medicine. It works primarily by influencing neurotransmitter activity associated with appetite and satiety.

The stated presentation contains 20 mg per tablet with 60 tablets in the package. This describes the labelled strength and quantity only. It should not be interpreted as a recommended dose, treatment schedule, or instruction for personal use.

For UK readers, the regulatory history of sibutramine is particularly important. It should not be presented as an ordinary dietary supplement or as a routine alternative to currently authorised weight-management treatments.

What Is Sibutramine?

Sibutramine was developed as an appetite-suppressing medicine intended to support weight management alongside lifestyle measures. Its pharmacological effects involve the reuptake of certain neurotransmitters, including serotonin and noradrenaline, which can influence appetite and satiety.

The medicine was previously marketed in several countries under different brand names. However, regulatory decisions concerning its safety have significantly affected its availability.

Sibu-Med is a product name associated with sibutramine preparations. A product name or advertised strength does not independently establish authenticity, regulatory approval, quality, or suitability for an individual.

20 mg/Tablets – 60 Tablets

The stated specification is 20 mg per tablet with 60 tablets in the package. If each tablet contains the labelled amount, the complete package represents a nominal 1,200 mg of sibutramine.

This calculation is included solely to clarify the stated product specification. It does not constitute a recommended daily amount, treatment duration, or personal dosing instruction.

When evaluating a tablet product, relevant information includes the active ingredient, strength, manufacturer, batch or lot number, expiry date, packaging integrity, storage requirements, and regulatory status.

Pharmacological Context

Sibutramine acts centrally and was investigated for its ability to influence appetite and energy balance. Its pharmacological activity differs from that of newer weight-management medicines, including therapies that work through specific metabolic hormone pathways.

The distinction is important when evaluating online claims. A product’s historical use for weight management does not mean that it remains authorised or appropriate for contemporary treatment.

Scientific evidence should be considered alongside regulatory assessments, safety data, clinical guidelines, and the specific circumstances of the patient.

Safety Considerations

Sibutramine has been associated with cardiovascular safety concerns. Effects can include increases in heart rate and blood pressure, which may be clinically significant in susceptible individuals.

Concerns about cardiovascular outcomes were an important factor in regulatory decisions regarding the medicine. Individuals with cardiovascular disease or relevant risk factors may face particular concerns.

Other possible adverse effects can include dry mouth, insomnia, headache, constipation, and changes in appetite. Drug interactions can also be important because sibutramine affects neurotransmitter systems.

Anyone who has taken an unregulated product containing sibutramine and develops concerning symptoms should seek appropriate medical attention.

Product Verification

Reliable documentation is important when evaluating any weight-management medicine obtained online. Useful information may include the active ingredient, tablet strength, manufacturer details, batch number, expiry date, packaging information, and evidence of legitimate regulatory status.

Online photographs, customer reviews, brand names, and marketing claims cannot independently confirm authenticity. Unregulated medicines can contain incorrect ingredients, inaccurate strengths, contaminants, or substances that are not disclosed on the label.

A pharmacist or appropriately qualified healthcare professional can provide guidance when the identity or safety of a medicine is uncertain.

UK Regulatory Considerations

UK readers should pay particular attention to the regulatory status of sibutramine. The medicine was withdrawn from the European market following concerns about cardiovascular risks identified through safety evidence. It is therefore inappropriate to present online availability as evidence that a sibutramine product is authorised for routine weight-management treatment in the UK.

The Medicines and Healthcare products Regulatory Agency (MHRA) provides medicine-safety and regulatory information relevant to the United Kingdom.

Responsible UK SEO content should clearly distinguish historical pharmaceutical information from currently authorised treatment options and should not encourage consumers to bypass legitimate medical or pharmacy channels.

Responsible Weight-Management Information

Effective weight management involves more than a single medication. Healthcare professionals may consider nutrition, physical activity, sleep, underlying health conditions, existing medicines, metabolic risk factors, and individual treatment goals.

Current treatment options should be discussed with a qualified healthcare professional rather than selected solely on the basis of online advertising or historical brand recognition.

A responsible product page should avoid guaranteed claims about rapid weight loss, appetite suppression, fat burning, or permanent results.

SEO Information for UK Readers

A strong UK-focused page can establish topical relevance using natural terms such as sibutramine, Sibu-Med, weight-management medicine, appetite suppressant, 20 mg tablets, 60-tablet presentation, cardiovascular safety, medicine regulation, UK weight management, pharmaceutical information, and product verification.

Using related terminology naturally helps avoid keyword stuffing while providing useful information for visitors researching the subject.

Product Summary

Sibu-Med (Sibutramine) 20 mg/Tablets – 60 Tablets describes a tablet presentation containing a stated strength of 20 mg per tablet and 60 tablets in the package. Assuming the labelled strength is accurate, the nominal total quantity is 1,200 mg of sibutramine.

The stated strength and package size do not establish authenticity, regulatory approval, medical suitability, or safety.

This page provides factual scientific and regulatory information only. It does not recommend self-administration, provide dosing instructions, or encourage non-prescribed use.

SIBU-MED (SIBUTRAMINE) (20 MG/TAB. – 60 TABS)SIBU-MED (SIBUTRAMINE) (20 MG/TAB. – 60 TABS)

Reviews

There are no reviews yet.

Be the first to review “SIBU-MED (SIBUTRAMINE) (20 MG/TAB. – 60 TABS)”

Your email address will not be published. Required fields are marked *

Shopping Cart